OTUD5 Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, IHC-P, IF, E |
---|---|
Primary Accession | Q96G74 |
Other Accession | EAW50723, 119571108 |
Reactivity | Human, Mouse, Rat |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | IgG |
Calculated MW | 60626 Da |
Application Notes | OTUD5 antibody can be used for detection of OTUD5 by Western blot at 1 - 2 µg/mL. Antibody can also be used for immunohistochemistry starting at 2.5 µg/mL. For immunofluorescence start at 20 µg/mL. |
Gene ID | 55593 |
---|---|
Target/Specificity | OTUD5; |
Reconstitution & Storage | OTUD5 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. |
Precautions | OTUD5 Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | OTUD5 (HGNC:25402) |
---|---|
Function | Deubiquitinating enzyme that functions as a negative regulator of the innate immune system (PubMed:17991829, PubMed:22245969, PubMed:23827681, PubMed:33523931). Has peptidase activity towards 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains (PubMed:22245969). Can also cleave 'Lys-11'-linked ubiquitin chains (in vitro) (PubMed:22245969). Acts via TRAF3 deubiquitination and subsequent suppression of type I interferon (IFN) production (PubMed:17991829). Controls neuroectodermal differentiation through cleaving 'Lys-48'-linked ubiquitin chains to counteract degradation of select chromatin regulators such as ARID1A, HDAC2 and HCF1 (PubMed:33523931). Acts as a positive regulator of mTORC1 and mTORC2 signaling following phosphorylation by MTOR: acts by mediating deubiquitination of BTRC, leading to its stability (PubMed:33110214). |
Cellular Location | Nucleus. |
Tissue Location | Expressed in various tissues, including the liver and placenta, as well as in peripheral blood leukocytes |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
OTUD5 Antibody: OTUD5 is a member of the OTU (ovarian tumor) domain-containing cysteine protease superfamily. The OTU domain confers deubiquitinase activity and OTUD5 has been shown to suppress the type I interferon (IFN-I)-dependent innate immune response by cleaving the polyubiquitin chain from TRAF3, an essential type I interferon adaptor protein. Cleavage results in disassociation of TRAF3 from a downstream signaling complex containing TBK1 and the disruption of the IFN-I signaling cascade, indicating that OTUD5 acts as a negative regulator of innate immune responses. It has been suggested that by suppressing IFN-I production, OTUD5 may function to inhibit the emergence of certain autoimmune disorders such as systemic lupus erythematosus. Multiple isoforms of OTUD5 are known to exist.
References
Kayagi N, Phung Q, Chan S, et al. DUBA: A deubiquitinase that regultes type I interferon production. Science2007; 318:1628-32.
Borodovsky A, Ovaa H, Kolli N, et al. Chemistry-based functional genomics reveals novel members of the deubiquitinating enzyme family. Chem. Biol.2002; 10:1149-59.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.